NCCN Updates in Bile Duct Cancer Put Focus on Precision Medicine
The addition of immunotherapy and targeted therapies to the NCCN guidelines in bile duct cancer means that tumor mutation profiling is now called for to guide treatment decisions.
Read More
Pemigatinib: EMA Panel Offers Conditional Nod for Pemigatinib
The EMA panel's nod pemigatinib in bile duct cancer is the latest positive news for the targeted therapy after its FDA approval and appearance in the NCCN Guidelines.
